Investor's Business Daily on MSN21h
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback